China Detains AstraZeneca (AZN) Staff in Data, Drug-import Probes - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN), PT $91.70, 'TL-01 final OS underwhelms', Shares down ~2.3%
September 9, 2024 3:07 PM EDTBofA Securities analyst Sachin Jain reiterated a Buy rating and $91.70 price target on AstraZeneca (NASDAQ: AZN).
The analyst comments "TL01 final OS underwhelming, puts TL01 approval at risk AZN presented final OS data for datopotamab from TL01 2L lung cancer study at World Lung,... More
AstraZeneca (AZN) Shares Down 3%+ Following Update
September 9, 2024 2:03 PM EDTAstraZeneca (NASDAQ: AZN) Shares Decline 3% Following Update.
At 2:50pm Eastern Time the company reported datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.
... More
AstraZeneca (AZN) Shares Down ~2.5% Following Update
September 9, 2024 1:58 PM EDTAstraZeneca (NASDAQ: AZN) Shares Down 2.5% Following Update.
At 2:50pm Eastern Time the company reported datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.
... More
